🕵️ Urogen Pharma Ltd. ($URGN)
SEC insider & ownership activity, last 12 months · CIK 1668243 · every row links its SEC filing
Over the last 12 months insiders sold $2.2M with no open-market buying against it. Schoenberg Mark sold $1.9M through a program of 7 sale notices averaging $245K (Jul–Jul). Morgan Stanley added 1.8% → 5.4%; Blackrock, Inc. added 5.0% → 5.2%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 3 sellers, $2.2M (17 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Schoenberg Mark | 0 | – | 11 | $1.9M | Jul 9, 2026 |
| Smith Jason Drew | 0 | – | 5 | $320K | Feb 3, 2026 |
| Degnan Chris | 0 | – | 1 | $37K | Oct 8, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| The Toronto-Dominion Bank | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| Morgan Stanley | 5.4% | 13G | Aug 6, 2025 | filing ↗ | |
| Blackrock, Inc. | 5.2% | 13G | Apr 27, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Schoenberg Mark | $400K | Jul 9, 2026 | filing ↗ |
| Schoenberg Mark | $350K | Jun 22, 2026 | filing ↗ |
| Schoenberg Mark | $140K | Jun 8, 2026 | filing ↗ |
| Schoenberg Mark | $300K | May 8, 2026 | filing ↗ |
| Schoenberg Mark | $261K | Feb 2, 2026 | filing ↗ |
| Schoenberg Mark | $250K | Nov 19, 2025 | filing ↗ |
| Schoenberg Mark | $16K | Sep 8, 2025 | filing ↗ |
| Smith Jason Drew | $29K | Sep 8, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material Modifications to Rights of Security Holders (3.03) | Jun 22, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 22, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 22, 2026 | filing ↗ |
| Other events (8.01) | Jun 2, 2026 | filing ↗ |
| Earnings (2.02) | May 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 6, 2026 | filing ↗ |
| Earnings (2.02) | Mar 2, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 2, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 26, 2026 | filing ↗ |
| New financial obligation (2.03) | Feb 26, 2026 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Aug 26, 2025 | filing ↗ |
| Shareholder vote (5.07) | Aug 26, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 26, 2025 | filing ↗ |
| Earnings (2.02) | Aug 7, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 7, 2025 | filing ↗ |